Analyst Price Target Update on IMS Health Holdings (NYSE:IMS)

IMS Health Holdings (NYSE:IMS): The mean estimate for the short term price target for IMS Health Holdings (NYSE:IMS) stands at $32 according to 9 Analysts. The higher price target estimate for the stock has been calculated at $38 while the lower price target estimate is at $26.

Many analysts have stated their opinion on the company shares. Equity Analysts at the Brokerage Firm, Wells Fargo, downgrades their rating on the shares of IMS Health Holdings (NYSE:IMS). Wells Fargo has a Market Perform rating on the shares. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on May 12, 2016. For the current week, the company shares have a recommendation consensus of Buy.

On the companys insider trading activities, The Securities and Exchange Commission has divulged that Knightly Kevin C, officer (SVP, Information Offerings) of Ims Health Holdings, Inc., had unloaded 19,231 shares at an average price of $28.5 in a transaction dated on November 23, 2015. The total value of the transaction was worth $548,084.

IMS Health Holdings (NYSE:IMS) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.01 points or 0.04% at $25.49 with 1,092,292 shares getting traded. Post opening the session at $25.5, the shares hit an intraday low of $25.43 and an intraday high of $25.73 and the price was in this range throughout the day. The company has a market cap of $8,409 million and the number of outstanding shares have been calculated to be 329,877,230 shares. The 52-week high of IMS Health Holdings (NYSE:IMS) is $33.515 and the 52-week low is $22.36.

IMS Health Holdings, Inc. (IMS) is an information and technology services company that provides solutions to its clients in the healthcare industry. The Company has its presence in over 100 countries. The Companys data set contains over 10 petabytes of data and over 500 million patient records. The Company serves healthcare organizations and life science companies, including pharmaceutical, biotechnology, consumer health and medical device manufacturers, as well as distributors, providers, payers, government agencies, policymakers, researchers and the financial community. The Companys principal offerings include national information offerings, sub-national information offerings, workflow analytics, real-world evidence (RWE) solutions, technology and applications and clinical solutions.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *